Literature DB >> 24493463

Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis.

George S Bloom1.   

Abstract

The defining features of Alzheimer disease (AD) include conspicuous changes in both brain histology and behavior. The AD brain is characterized microscopically by the combined presence of 2 classes of abnormal structures, extracellular amyloid plaques and intraneuronal neurofibrillary tangles, both of which comprise highly insoluble, densely packed filaments. The soluble building blocks of these structures are amyloid-β (Aβ) peptides for plaques and tau for tangles. Amyloid-β peptides are proteolytic fragments of the transmembrane amyloid precursor protein, whereas tau is a brain-specific, axon-enriched microtubule-associated protein. The behavioral symptoms of AD correlate with the accumulation of plaques and tangles, and they are a direct consequence of the damage and destruction of synapses that mediate memory and cognition. Synapse loss can be caused by the failure of live neurons to maintain functional axons and dendrites or by neuron death. During the past dozen years, a steadily accumulating body of evidence has indicated that soluble forms of Aβ and tau work together, independently of their accumulation into plaques and tangles, to drive healthy neurons into the diseased state and that hallmark toxic properties of Aβ require tau. For instance, acute neuron death, delayed neuron death following ectopic cell cycle reentry, and synaptic dysfunction are triggered by soluble, extracellular Aβ species and depend on soluble, cytoplasmic tau. Therefore, Aβ is upstream of tau in AD pathogenesis and triggers the conversion of tau from a normal to a toxic state, but there is also evidence that toxic tau enhances Aβ toxicity via a feedback loop. Because soluble toxic aggregates of both Aβ and tau can self-propagate and spread throughout the brain by prionlike mechanisms, successful therapeutic intervention for AD would benefit from detecting these species before plaques, tangles, and cognitive impairment become evident and from interfering with the destructive biochemical pathways that they initiate.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24493463     DOI: 10.1001/jamaneurol.2013.5847

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  508 in total

1.  Polyadenylation of nascent RNA during the embryogenesis of Ilyanassa obsoleta.

Authors:  J R Collier
Journal:  Exp Cell Res       Date:  1975-10-15       Impact factor: 3.905

Review 2.  The Role of Proteases in Hippocampal Synaptic Plasticity: Putting Together Small Pieces of a Complex Puzzle.

Authors:  Ivan L Salazar; Margarida V Caldeira; Michele Curcio; Carlos B Duarte
Journal:  Neurochem Res       Date:  2015-11-07       Impact factor: 3.996

Review 3.  Dissecting Complex and Multifactorial Nature of Alzheimer's Disease Pathogenesis: a Clinical, Genomic, and Systems Biology Perspective.

Authors:  Puneet Talwar; Juhi Sinha; Sandeep Grover; Chitra Rawat; Suman Kushwaha; Rachna Agarwal; Vibha Taneja; Ritushree Kukreti
Journal:  Mol Neurobiol       Date:  2015-09-09       Impact factor: 5.590

4.  Association of Head Injury with Brain Amyloid Deposition: The ARIC-PET Study.

Authors:  Andrea L C Schneider; Elizabeth Selvin; Menglu Liang; Lawrence Latour; L Christine Turtzo; Silvia Koton; Josef Coresh; Thomas Mosley; Christopher T Whitlow; Yun Zhou; Dean F Wong; Geoffrey Ling; Rebecca F Gottesman
Journal:  J Neurotrauma       Date:  2019-05-23       Impact factor: 5.269

5.  Activation of the Cannabinoid Type 2 Receptor by a Novel Indazole Derivative Normalizes the Survival Pattern of Lymphoblasts from Patients with Late-Onset Alzheimer's Disease.

Authors:  Patricia Del Cerro; Carolina Alquézar; Fernando Bartolomé; Pedro González-Naranjo; Concepción Pérez; Eva Carro; Juan A Páez; Nuria E Campillo; Ángeles Martín-Requero
Journal:  CNS Drugs       Date:  2018-06       Impact factor: 5.749

Review 6.  It's all about tau.

Authors:  Cheril Tapia-Rojas; Fabian Cabezas-Opazo; Carol A Deaton; Erick H Vergara; Gail V W Johnson; Rodrigo A Quintanilla
Journal:  Prog Neurobiol       Date:  2018-12-31       Impact factor: 11.685

7.  Somatodendritic accumulation of Tau in Alzheimer's disease is promoted by Fyn-mediated local protein translation.

Authors:  Chuanzhou Li; Jürgen Götz
Journal:  EMBO J       Date:  2017-09-01       Impact factor: 11.598

Review 8.  Dual roles of astrocytes in plasticity and reconstruction after traumatic brain injury.

Authors:  Yunxiang Zhou; Anwen Shao; Yihan Yao; Sheng Tu; Yongchuan Deng; Jianmin Zhang
Journal:  Cell Commun Signal       Date:  2020-04-15       Impact factor: 5.712

9.  mTOR and neuronal cell cycle reentry: How impaired brain insulin signaling promotes Alzheimer's disease.

Authors:  Andrés Norambuena; Horst Wallrabe; Lloyd McMahon; Antonia Silva; Eric Swanson; Shahzad S Khan; Daniel Baerthlein; Erin Kodis; Salvatore Oddo; James W Mandell; George S Bloom
Journal:  Alzheimers Dement       Date:  2016-09-29       Impact factor: 21.566

Review 10.  Pharmacophore-based models for therapeutic drugs against phosphorylated tau in Alzheimer's disease.

Authors:  Jangampalli Adi Pradeepkiran; Arubala P Reddy; P Hemachandra Reddy
Journal:  Drug Discov Today       Date:  2018-11-16       Impact factor: 7.851

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.